linjc16/ctgov huggingface dataset:
Modified Trabeculectomy for Glaucoma Surgery

Study Overview
=================
Brief Summary
-----------------
A combination of hypotony, flat anterior chamber and choroidal detachment is the most common complications after filtering surgery. The purpose of this study is to present a new modification in standard trabeculectomy technique to reduce such complications.

Detailed Description
-----------------
Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane. Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm. The horizontal distance between each point is 3.5 mm Figure(1). The application of the cautery continue till the color of the tissue becomes brown. Then with aid of a 23-gauge needle we penetrate these cauterized points to create 4 holes, each of them is nearly 0.3-0.5 mm in length (the opening of each hole takes the shape of a slit). Through one of these holes iridectomy is done. These holes drain the aqueous under the scleral flap with anatomical preservation of tissue in between. Close the scleral flap by two 10-0 nylon suture.

Official Title
-----------------
Modified Trabeculectomy a New Procedure for Glaucoma Surgery

Conditions
-----------------
IOP Decreased

Intervention / Treatment
-----------------
* Procedure: MODIFIED TRABECULECTOMY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1ery glacouma Exclusion Criteria: Previous surgery

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 62 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MODIFIED TRABECULECTOMY<br>Recta-angular scleral flap (one half the scleral thickness) is dissected,reaching 2 mm into the cornea. The dissection through the cornea is carried out with great care, leaving only thin corneal stroma over Descement's membrane. Application of direct heat cautery using a prob Imm in size (the prob was heated for 45 seconds) the cautery was applied at 4 points two of them just in front of blue corneal line and the other two at 2 mm anterior to the blue line, the diameter of each point is 1 - 1.5 mm. | Procedure: MODIFIED TRABECULECTOMY<br>* Rectangular scleral flap<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP | Decreased IOP with normal depth anterior chamber measured by Tonopen | 6 month |
Alzheimer's Disease Prevention Trial

Study Overview
=================
Brief Summary
-----------------
This is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.

Detailed Description
-----------------
PREventing Postmenopausal memory loss and Alzheimer's with Replacement Estrogens (PREPARE) is a double-blind-placebo controlled trial to determine whether estrogen (or estrogen and progesterone) can delay the onset of memory loss or Alzheimer's Disease in elderly women with a family history of the disease.

Official Title
-----------------
Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.

Conditions
-----------------
Alzheimer Disease, Memory Disorders

Intervention / Treatment
-----------------
* Drug: Estrogen
* Drug: Estrogen and Progesterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women 65 or older with a family history of memory problems not currently on estrogen. Exclusion Criteria: Significant neurological impairment Current estrogen use History of breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Estrogen|nan|
|Drug: Estrogen and Progesterone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer's disease, memory loss, Estrogen
Computerized Guideline in Heart Failure: Implementation Process and Impact Evaluation

Study Overview
=================
Brief Summary
-----------------
Objective: To assess the effectiveness of implementation process of an electronic Heart Failure guideline in primary care in the city of Barcelona.

Detailed Description
-----------------
Design: Two types of design will be applied, according to the specific aims. On the one hand it is a cross-sectional and a qualitative study, on the other hand it is quasi-experimental study. Pre-post intervention with a control group, as well as, of repeated measures in the intervention group

Official Title
-----------------
Implementation Process and Impact of the Heart Failure Electronic Clinical Guideline in the Catalan Health Institute Primary Care Health Board

Conditions
-----------------
Chronic Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: general and nurse primary care practitioners working in Barcelona and Girona for the Health Catalan Institute. Managers involved in implementation process for the computerised clinical guideline in Barcelona from the Health Catalan Institute. patients with diagnoses of Heart Failure according to ICD-10 according to general practice clinical records. Exclusion Criteria: Managers and general and nurse primary care practitioners working in Barcelona health Centres where there were any other quality improvement project related to Heart failure at the time of the intervention which we are evaluating. Managers from the control group (Girona). patients with a mental health disorder or terminal illness

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 control group<br>Computerized data collection of outcome measures in usual care | |
| 2 intervention group<br>Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACE/ARBs, ACE/ARBs+BB, hospitalisation rates, survival rate, reliability/ usability/applicability of computerised guideline, economic measurements |  | 2005 to 2007 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic heart failure, Computerized clinical guidelines, Primary care
Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing

Study Overview
=================
Brief Summary
-----------------
The aim of this retrospective study is to analyze if nighttime antimuscarincs may be more effective in treating patients with nocturia.

Conditions
-----------------
Overactive Bladder Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent tolterodine SR treatment once per day for 12 weeks in Department of Obstetrics & Gynecology in National Taiwan University Hospital and Far Eastern Memorial Hospital Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bladder diary | To clarity any difference of reduction in the episodes of nocturia between these two groups. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and Urgency | To clarity any difference of reduction in the episodes of urinary frequency and urgency between these two groups. | 3 months |
Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether continuous infusion of palonosetron after its prophylactic single injection can further reduce the incidence of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery.

Official Title
-----------------
Effect of Continuous Infusion of Palonosetron Following Single Prophylactic Injection of Palonosetron for Preventing Postoperative Nausea and Vomiting

Conditions
-----------------
Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Drug: continuous infusion of palonosetron added to prophylactic single injection of palonosetron
* Drug: continuous infusion of normal saline added to prophylactic single injection of palonosetron


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA Physical Status 1 or 2 Elective gynaecological laparoscopic surgery of ≥ 1h duration Exclusion Criteria: Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation Vomiting or retching in the 24 h preceding surgery Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry Ongoing vomiting from gastrointestinal disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: continuous infusion<br>continuous infusion of palonosetron added to prophylactic single injection of palonosetron | Drug: continuous infusion of palonosetron added to prophylactic single injection of palonosetron<br>* continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg<br>|
| Placebo Comparator: singel injection<br>continuous infusion of normal saline added to prophylactic single injection of palonosetron | Drug: continuous infusion of normal saline added to prophylactic single injection of palonosetron<br>* continuous infusion of normal saline after single injection of palonosetron 0.075mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of postoperative nausea and vomiting |  | 24 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of nausea |  | for 24 hours after sugery |
Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN

Study Overview
=================
Brief Summary
-----------------
Sub arachnoid hemorrhage consecutive to intracranial aneurysm rupture is a devastating disease. Predictors of intracranial aneurysm rupture are limited and focus mainly on size and location. Platelet activation may have a deleterious role on aneurysm rupture. The assumption is that patients with ruptured intracranial aneurysm will present a higher rate of platelet activation compared to patients with non ruptured aneurysms.

Official Title
-----------------
Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN

Conditions
-----------------
Intracranial Aneurysms, Ruptured Aneurysm

Intervention / Treatment
-----------------
* Other: Collection of blood sample in aneurysm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 and over Patient presenting a single or multiple aneurysm Patient presenting an intracranial aneurysm for which an intervention is planned (endovascular treatment or surgery) : elective intervention for an unruptured aneurysm or emergency surgery for a broken aneurysm Exclusion Criteria: - Pregnant or breast feeding woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Collection of blood sample in aneurysm|In case of an endovascular treatment : A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure. Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit. In case of a surgery treatment : A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery. A Tissue sample will be taken during the surgery Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with platelet activation | comparison of this proportion between patients with ruptured versus non ruptured intracranial aneurysm | in the 7 days before embolisation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intracranial aneurysms, ruptured aneurysm, platelet activity
The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance

Study Overview
=================
Brief Summary
-----------------
This study will investigate the effects of hydrothermally modified starch (SuperStarch) in adults. SuperStarch, originally developed as a drink for children with glycogen storage disease, is a slow digestible carbohydrate, maintaining blood sugar levels over extended periods. Therefore, it could be beneficial to exercise and mental performance, and could possibly have fat loss effects by increasing feelings of fullness. In this study, measures will be taken in 25 men to assess mental function, appetite, and metabolism to determine the processes involved in possible fat loss.

Official Title
-----------------
The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance

Conditions
-----------------
Fatigue

Intervention / Treatment
-----------------
* Other: Carbohydrate drink
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, 18 to 35 year old man or woman. Exclusion Criteria: smoker pregnancy taking part in other research. followed a weight loss diet in the previous 6 months. history of gastrointestinal, endocrine, cardiovascular disease or diabetes. neurological or psychiatric condition that may cause cognitive dysfunction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Carbohydrate drink<br>Ingest 500ml (1g/kg) prior to metabolic measures. | Other: Carbohydrate drink<br>* Ingest 500ml (1g/kg) prior to metabolic measures.<br>Other: Placebo<br>* Ingest 500ml of placebo prior to metabolic measures.<br>|
| Placebo Comparator: Placebo<br>Ingest 500ml of placebo prior to metabolic measures. | Other: Carbohydrate drink<br>* Ingest 500ml (1g/kg) prior to metabolic measures.<br>Other: Placebo<br>* Ingest 500ml of placebo prior to metabolic measures.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen Consumption |  | Four 10 minute measures throughout 90 min protocol (1 day). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appetite ratings |  | Four appetite ratings throughout 90 min protocol (1 day). | 
| Cognitive function |  | 2 computerized tests (Stroop Test, Trail Making test) repeated 3 times throughout 90 min protocol (1 day). |
Effect of Pyridorin in Patients With Diabetic Nephropathy

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes

Conditions
-----------------
Diabetic Nephropathy

Intervention / Treatment
-----------------
* Drug: Pyridorin (pyridoxamine dihydrochloride)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1 Hemoglobin A1C <=12% at week -2 Patients with diagnosis of diabetic nephropathy as defined by Serum Creatinine <=2.0 mg/dL at weeks -2 and -1 Urinary albumin excretion >=300 mg/24 hours at week -2 Diagnosis of diabetic retinopathy Creatinine clearance >=40 mL/min at weeks -2 and -1 Voluntary written consent to participate in this study Exclusion Criteria: History of allergic or adverse response to any B vitamin History of major cardiovascular or cerebrovascular events History of cancer except adequately treated basal or squamous cell carcinoma of the skin History of diabetic ketoacidosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pyridorin (pyridoxamine dihydrochloride)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetic nephropathy, Advanced Glycation Endproduct Inhibitor, Pyridorin, Pyridoxamine
Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits

Study Overview
=================
Brief Summary
-----------------
This study is designed to further investigate the use of a modified Atkins diet for children with intractable, daily seizures. It is a follow-up to a study recently completed by our institution. In this 6-month study, children will be randomized to either 10 or 20 grams of carbohydrate per day, then crossed over to the opposite amount at 3 months.

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Behavioral: Modified Atkins diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 3-18 Daily seizures or 7 per week Failed at least 2 anticonvulsants Exclusion Criteria: Prior use of the Atkins diet for over 1 week Significant heart, liver, or kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Modified Atkins diet|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seizure control |  | 6 months | 
| Ketosis |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability |  | 6 months | 
| Safety - cholesterol, kidney function, weight |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Epilepsy, Ketosis, Atkins, seizures